High Profile HealthCare Companies: Leading Pharma Company Secures New Patents
CORAL SPRINGS, Florida, February 14, 2013
CORAL SPRINGS, Florida, February 14, 2013 /PRNewswire/ --
FinancialNewsMedia.com "Active Health Stocks to Watch" for today: Crown
Marketing Pharmaceuticals, Amarin Corporation (NASDAQ: AMRN ), Keryx
Biopharmaceuticals Inc. (NASDAQ: KERX ), Eli Lilly and Company (NYSE: LLY ),
Medtronic, Inc. (NYSE: MDT ), RPX Corporation (NASDAQ: RPXC ).
Crown Marketing Pharmaceuticals closed up over 16% in trading yesterday
closing at $0.128 per share.Crown Marketing Pharmaceuticals announced today
that Patents for its Controlled Drug Delivery Technology (CDDT) have been
approved and registered in South Africa. This is Crown Marketing
Pharmaceuticals's second major announcement regarding the approval of new
Patents following last week's news it had also secured Patents in Norway.
Crown is continuing to secure its worldwide patent rights as it pursues novel
applications of its drug delivery technology.Crown Marketing Pharmaceuticals
also announced last week on February 7th the company has begun to review
positive in vivo test results by examining blood plasma levels in test
subjects using Crown's Controlled Drug Delivery Technology (CDDT). A clinical
trial was conducted using 300 mg of Dexibuprofren Lysine and found that the
blood plasma levels tracked the in vitro test results conducted earlier. The
clinical trial appears to validate our belief and claims that because of the
controllable diffusion dynamics and our mathematical modeling, we can predict
with a high degree of certainty the release kinetics. For more details
regarding Crown's CDDT applications, go to http://crowncddt.com/technology/
Stay informed on Crown Marketing developments by getting FREE news alerts &
updates delivered directly to your mobile phone by texting STOCK to 545454
from your cellular device or visit http://cwnm.mobi for more details.
Amarin Corporation plc (NASDAQ: AMRN ) closed up in trading yesterday closing
at $8.58 per share on 2.84Million shares. AMRN is a biopharmaceutical company
focused on the commercialization and development of therapeutics to improve
cardiovascular health, that announced this week that the United States Patent
and Trademark Office (USPTO) has published notification of Notice of Allowance
for U.S. Patent Application Serial Number 13/614,129. This application
includes claims intended to protect the Vascepa (icosapent ethyl) indication
approved by the U.S. Food and Drug Administration (FDA) based on Amarin's
MARINE clinical trial results.
Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX ) closed up slightly in trading
yesterday closing at $7.11 per share on 5.47Million shares. KERX is focused
on the acquisition, development and commercialization of medically important
pharmaceutical products for the treatment of renal disease. Keryx is
developing Zerenex (ferric citrate), an oral, ferric iron-based compound that
has the capacity to bind to phosphate and form non-absorbable complexes.
Zerenex has completed a U.S.-based Phase 3 clinical program for the treatment
of hyperphosphatemia (elevated phosphate levels) in patients with end-stage
renal disease, conducted pursuant to a Special Protocol Assessment (SPA)
agreement with the FDA, and Keryx expects to submit an NDA with the FDA and a
MAA with the EMA in the second quarter of 2013.
Eli Lilly and Company (NYSE: LLY ) closed up slightly in trading yesterday
closing at $53.44 per share on 4.38Million shares. An announcement was issued
after the close yesterday that LLY has entered into a master collaboration
agreement with QIAGEN (NASDAQ: QGEN) for the development and commercialization
of companion diagnostics for pairing with Lilly investigational and approved
medicines across all therapeutic areas. The agreement builds on QIAGEN and
Lilly's past work together. Companion diagnostics unlock a patient's molecular
information in order to guide treatment decisions for specific cancers or
other diseases. Financial terms of the agreement are not being disclosed.
Medtronic, Inc. (NYSE: MDT ) closed down slightly in trading yesterday closing
at $46.99 per share on 3.04Million shares, but was up in After-Market trading.
MDT announced after the markets closed on Wednesday that it has received Food
and Drug Administration (FDA) clearance for its AIRvance(TM) Bone Screw System
that allows surgeons to perform a hyoid suspension procedure independently or
in combination with other procedures for the treatment of obstructive sleep
apnea (OSA). Under the previous FDA clearance the hyoid suspension procedure
was indicated as an adjunct to the tongue suspension procedure. This latest
FDA clearance makes the AIRvance System the only combined system available for
performing a hyoid suspension procedure as well a tongue suspension procedure.
RPX Corporation (NASDAQ: RPXC ) closed up over 22% in trading yesterday
closing at $13.05 pre share on 1.1Million shares. RPXC is a leading provider
of patent risk management solutions, announced yesterday its financial results
for the fourth quarter and year ended December 31, 2012. RPXC Revenue for the
fourth quarter of fiscal 2012 totaled $51.6 million, up 22% from the prior
year period and Revenue for fiscal 2012 totaled $197.7 million, up 28% from
fiscal 2011. "RPX reported a solid 2012, capped by a strong fourth quarter
with progress in client growth, patent acquisition activity, and the roll out
of our insurance service," said Chief Executive Officer John Amster.
Other Healthcare companies to monitor for new developments are Bond
Laboratories, Inc ( BNLB ), an international provider of innovative and
proprietary nutritional supplements for health conscious consumers; YaFarm
Technologies, Inc. ( YFRM ) subsidiary, The Integrative Stem Cell Institute
(ISCI), is a premier provider of point-of-care, stem cell-based therapies; and
Bio-Matrix Scientific Group, Inc. ( BMSN ), a biotechnology company developing
regenerative medicine therapies.
FinancialNewsMedia.com is leading provider of third party publishing & news
dissemination services. If you would like more information regarding our
news coverage solutions, please visit http://www.financialnewsmedia.com
for more details.
DISCLAIMER: FN Media Group LLC (FNMG) is a third party publisher and news
dissemination service provider, which disseminates electronic information
through multiple online media channels. FNMG is NOT affiliated in any manner
with any company mentioned herein. FNMG and its affiliated companies are a
news dissemination and financial marketing solutions provider and are NOT a
registered broker/dealer/analyst/adviser, holds no investment licenses and may
NOT sell, offer to sell or offer to buy any security. FNMG's market updates,
news alerts and corporate profiles are NOT a solicitation or recommendation to
buy, sell or hold securities. The material in this release is intended to be
strictly informational and is NEVER to be construed or interpreted as research
material. All readers are strongly urged to perform research and due
diligence on their own and consult a licensed financial professional before
considering any level of investing in stocks. The companies that are
discussed in this release may or may not have approved the statements made in
this release. FNMG is not liable for any investment decisions by its readers
or subscribers. Investors are cautioned that they may lose all or a portion
of their investment when investing in stocks.
FNMG HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains "forward-looking statements" within the meaning of
Section 27A of the Securities Act of 1933, as amended, and Section 21E the
Securities Exchange Act of 1934, as amended and such forward-looking
statements are made pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. "Forward-looking statements"
describe future expectations, plans, results, or strategies and are generally
preceded by words such as "may", "future", "plan" or "planned", "will" or
"should", "expected," "anticipates", "draft", "eventually" or "projected". You
are cautioned that such statements are subject to a multitude of risks and
uncertainties that could cause future circumstances, events, or results to
differ materially from those projected in the forward-looking statements,
including the risks that actual results may differ materially from those
projected in the forward-looking statements as a result of various factors,
and other risks identified in a company's annual report on Form 10-K or 10-KSB
and other filings made by such company with the Securities and Exchange
Commission. You should consider these factors in evaluating the
forward-looking statements included herein, and not place undue reliance on
such statements. The forward-looking statements in this release are made as of
the date hereof and FNMG undertakes no obligation to update such statements.
Contact Information: Company: FN Media Group, LLC Contact email:
firstname.lastname@example.org U.S. Phone: +1-954-345-0611 URL:
Press spacebar to pause and continue. Press esc to stop.